ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Frederickson Resigns As NIH Director, Says He Wants “One More Career: As Scientist, Physician

June 25, 1981

Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program

August 27, 1982

Turmoil in Texas: AVEO, DePinho Joined at the Hip (Pocket)

May 8, 2013

NSABP Researcher Committed Misconduct, NIH Investigation Finds

March 18, 1994

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

NCI Study Fails To Support Finding Of Excess Cancer In Utah Nuclear Fallout Areas

January 23, 1987